Document is current
Any future updates will be listed below
-
Authors
Hektoen, Helga H.
Tsuruda, Kaitlyn M. https://orcid.org/0000-0001-8749-6237
Fjellbirkeland, Lars
Nilssen, Yngvar
Brustugun, Odd Terje
Andreassen, Bettina K. https://orcid.org/0000-0001-5087-2913
-
Funding
Funding for this research was provided by:
Ministry of Health and Care Services | Helse Sør-Øst RHF
- License Information
-
More Information
Article History
Received: 1 February 2024
Revised: 23 October 2024
Accepted: 24 October 2024
First Online: 3 November 2024
Competing interests
: Odd Terje Brustugun declares receiving grants or contracts from Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Pfizer, Roche/Genentech and Ultimovacs; receiving payment or honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi Genzyme, Takeda; having consulting/advisory roles for Janssen, MSD, Boehringer Ingelheim. The remaining authors declare no conflicts of interest.
: Use and reporting of de-identified data from the CRN were covered by the CRN’s regulations of collection and treatment of health information. Use, linkage and reporting of de-identified data from all other registries was approved by the regional ethics committee (2018/775/REK sør-øst B) and all involved registries. The study was performed in accordance with the Declaration of Helsinki.
